Industry: Healthcare Region: US Transaction Price: USD 1 million Transaction Method: Equity Investment
Project introduction:
Age-related advanced macular degeneration (AMD) is the main cause of vision loss in the elderly. For most people, the current treatment method of frequent, expensive, continuous and lifelong direct injection of Anti-VEGF (anti-VEGF drugs are generally anti-angiogenic growth factors) into the eyes is unaffordable. Up to 60% of patients ha-ve no effect on Anti-VEGF injection, which may be due to their subtypes, usually polypoid choroidal angiopathy (PCV).
BetaCurve™ is expected to be a special treatment for PCV approved by FDA. Gently bend at the back of the eye, and use the fiber light source to accurately trans-mit therapeutic beta rays to the affected area for placement guidance.
A company in the clinical stage in California has developed a patented radiotherapy equipment, which uses BetaCurve™ therapy method to treat various retinal diseases. Recently, it was approved by FDA to conduct a complete multi-center key research to treat PCV.
Intellectual property rights: 6 trademarks, 13 design patents and 73 utility patents.
Advantages of the project:
Cost-effective
Disposable treatment
Accurate dose
10-minute treatment procedure
Accurate positioning.
Comparison of therapeutic effects:
Therapeutic effect of Anti-VEGF:
Treat twigs (capillaries), but not roots and trunk (arterialized blood vessels).
May temporarily improve vision.
Over time, anti-VEGF will lose its effectiveness, leading to blindness.
Frequent and continuous injections are required.
Therapeutic effect of beta-ray:
Treat twigs (capillaries) and roots and trunk (arterialized blood vessels)
Early studies show the ability to stabilize or improve vision for a long time.
As time goes by, radiotherapy can keep its effectiveness, which may prevent blindness.
Disposable treatment
Market opportunities:
20 million people suffer from advanced macular degeneration (AMD), and the sales of anti-VEGF are over $15 billion. Up to 60% of people with anti-VEGF treatment ha-ve poor therapeutic effect.
Cooperation mode: Series A financing of 10 million USD.